AUTHORS
Abdulraheem Yacoub, MD, Aniket Bankar, MD, MSc, DM, MBBS2, Andrew T Kuykendall, MD3, Kristen Pettit, MD4, Jiri Mayer, MD5, Valentín García Gutiérrez I, MD6, Alessandro Lucchesi, MD, PhD7, Naveen Pemmaraju, MD8, Harinder Gill, MBBS, MD9, Daniel Sasca, MD10, Timothy Devos, MD, PhD11, Arturo Molina, MD, MS12, Phil Dinh13, Xuzhi Wang14, Alisa Harrigan15, Frank Campana, MD16, Joseph Shatzel, MD17
AFFILIATIONS
1 University of Kansas Cancer Center, Westwood, Kansas, United States
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, United States
4 University of Michigan, Ann Arbor, Michigan, United States
5 University Hospital Brno and Masaryk University, Brno, Czech Republic
6 Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain
7 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Hong Kong, Hong Kong, Hong Kong
10 University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
11 Department of Haematology, University Hospitals Leuven and Department of Microbiology, Immunology, and Transplantation Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium
12 Protagonist Therapeutics, Inc., Newark, California, United States
13 Protagonist Therapeutics, Inc., Newark, California, United States
14 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
15 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
16 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
17 Oregon Health & Science University, Portland, Oregon, United States
ABSTRACT
Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis, elevated hematocrit (Hct), and increased blood viscosity. Current standard of care aims to maintain Hct <45% and includes phlebotomy (PHL) with/without cytoreductive therapies (CRT), such as hydroxyurea. Rusfertide is a first-in-class, self-administered subcutaneous peptide that mimics the endogenous hormone hepcidin, the body’s principal regulator of iron homeostasis. In the phase 3 VERIFY study (NCT05210790), rusfertide or placebo (PBO) were added to ongoing PV therapy; rusfertide achieved the primary endpoint of clinical response (absence of PHL eligibility; P<0.0001) in both low- and high-risk patients (pts), and all key secondary endpoints (P<0.05 for each) vs PBO. Prior treatment exposure, cumulative PHL burden, and disease biology may differ between pts with newly diagnosed vs longer-standing disease. Whether these differences influence response to rusfertide is unknown; therefore, this post hoc analysis evaluated the effect of rusfertide on erythrocytosis control in pts with newly diagnosed (≤1 year [yr] since diagnosis) vs pts with longer-duration PV (>1 yr since diagnosis). PV duration was defined as the interval from the date of estimated PV onset to informed consent.
Methods: Pts with PV requiring frequent PHL with/without CRT to maintain Hct <45% were randomized 1:1 to receive once weekly subcutaneous rusfertide or PBO for 32 weeks (Wks), stratified by ongoing PV therapy. The primary endpoint was the proportion of pts achieving a clinical response (absence of PHL eligibility) from Wks 20 to 32. Key secondary endpoints were assessed from Wks 0 to 32 and included mean number of PHLs and proportion of pts with Hct <45%. Safety endpoints included treatment-emergent adverse events (TEAEs) and treatment discontinuations due to TEAEs.
Results: At data cutoff (May 27, 2025), 293 pts were randomized 1:1 to rusfertide or PBO, including 55 pts with PV duration ≤1 yr (rusfertide n=31; PBO n=24) and 238 pts with PV duration >1 yr (rusfertide n=116; PBO n=122). At baseline, median age was 57 yrs for both PV duration subgroups. Median (range) duration of PV was 0.7 yrs (0.2–1.0) in pts with PV ≤1 yr and 4.0 yrs (1.0–29.2) in pts with PV >1 yr; median (range) number of PHLs was 5.0 (1.0–11.0) and 4.0 (2.0–9.0), respectively. The proportion of pts with high-risk PV (aged ≥60 yrs and/or prior thromboembolic event) was 45.5% and 47.1% among pts with PV ≤1 yr and >1 yr, respectively. Concurrent CRT was reported in 45.5% of pts with PV ≤1 yr and 57.6% of pts with PV >1 yr; hydroxyurea was most common (PV ≤1 yr: 36.4%; PV >1 yr: 39.5%). During Wks 20–32, among the PV ≤1 yr subgroup, clinical response rates numerically favored rusfertide-treated pts compared with PBO (71.0% vs 45.8%, respectively; P=0.0557), despite the small sample size. In the PV >1 yr subgroup, the clinical response rate was significantly higher in pts (78.4%) vs PBO (30.3%; P<0.0001). Mean (standard deviation) number of PHLs from baseline to Wk 32 was lower with rusfertide vs PBO, respectively, regardless of PV duration (PV ≤1 yr: 0.4 [0.8] vs 1.8 [1.5]; PV >1 yr: 0.5 [1.2] vs 1.8 [1.5]). A significantly higher proportion of pts maintained Hct <45% in the rusfertide vs PBO arms, respectively, between Weeks 0 and 32: 61.3% vs 12.5% (P<0.0004) in pts with PV ≤1 yr and 62.9% vs 14.8% (P<0.0001) in pts with PV >1 yr. TEAEs were reported in 86.7% vs 91.7% of pts treated with rusfertide vs PBO, respectively, among pts with PV ≤1 yr, and 91.3% vs 85.2% among pts with PV >1 yr. TEAEs led to rusfertide discontinuation in two and six pts in the PV ≤1 yr and PV >1 yr subgroups, respectively. The most common TEAE in rusfertide-treated pts was injection site erythema in both PV ≤1 yr (33.3%) and PV >1 yr (33.0%) subgroups. A limitation of the results is the small number of pts in the PV ≤1 yr subgroup.
Conclusions: Clinical response, Hct control, and PHL reduction consistently favored rusfertide compared with PBO, regardless of disease duration. Both subgroups (≤1 yr since diagnosis and >1 yr since diagnosis) had similar safety profiles. These findings support the clinical benefit of rusfertide in pts with newly diagnosed and longer-duration PV, including those receiving concurrent CRT.
DISCLOSURES
Abdulraheem Yacoub, MD: Karyopharm - Honoraria; Novartis - Honoraria; Servier - Honoraria; Blueprint - Honoraria; Incyte - Honoraria; GlaxoSmithKline - Honoraria; Geron - Honoraria; Sobi - Honoraria; AbbVie - Honoraria; CTI Pharma - Research Funding; Stemline Therapeutics - Research Funding